HLA-G in cancer: a way to turn off the immune system.
The expression of HLA-G in cancer represents a strategy employed by tumors to avoid immune destruction. Indeed, this non-classical HLA class I molecule suppresses various immune cell functions through binding to inhibitory receptors. We here review the studies done by our group that described for the first time (i) HLA-G expression in malignancies such as melanomas, renal and breast carcinomas. (ii) the up-regulation of HLA-G gene transcription by tumor environmental factors such as cytokines and stress and by agents used in chemotherapy such as demethylating molecules, and (iii) the biological relevance of such HLA-G expression in the evasion of malignant cells from antitumor immune response.
Rouas-Freiss
Nathalie
N
Senrvice de Recherches en Hémato-Immunologie, CEA-DSV-DRM, Hôpital Saint-Louis, 1UH, 1 Avenue Claude-Vellefaux, 75475 Paris 10, France. freiss@dsvidf.cea.fr
Moreau
Philippe
P
Menier
Catherine
C
Carosella
Edgardo D
ED
D045744:Cell Line, Tumor; D016207:Cytokines / Q000378:metabolism; D019175:DNA Methylation; D006680:HLA Antigens / Q000502:physiology*; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic; D015854:Up-Regulation
D016207:Cytokines; D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I